Growth financing Leverage REVA Medical's recent Series B funding of 45 million to position partnerships or co-development opportunities in advanced vascular therapies and to propose joint commercialization or preferred supplier arrangements for the Fantom Encore platform and other bioresorbable polymer technologies.

Clinical program focus Target engagement with clinical program stakeholders to offer complementary devices, services, or data collaboration around MOTIV scaffold trials, patient outcomes research, and post-market surveillance to strengthen the value proposition for hospitals adopting bioresorbable solutions.

Technical leverage Align sales efforts around REVA's Tyrocore polymer and bioresorbable scaffold technology by proposing turnkey integration packages, regulatory support, and eQMS/compliance tooling partnerships to streamline adoption and shorten time-to-value for medical centers.

Market positioning Position Fantom Encore against traditional metallic stents by emphasizing artery healing restoration and resorption benefits to gain interest from hospitals seeking next-generation CAD solutions, procurement teams evaluating long-term cost and patient outcomes.

Strategic partnerships Explore collaborations with larger manufacturers or distributors in the medical device space to scale reach, including potential OEM relationships, co-marketing, and distribution agreements that leverage REVA's mid-size company profile and growth trajectory.